Читать книгу Clinical Pharmacology and Therapeutics - Группа авторов - Страница 152

1 Drummond MF, Sculpher MJ, Claxton K, Torrance GW and Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes, 4th Edn, 2015. Oxford University Press, Oxford

2 Gani R, Giovannoni G, Bates D, et al. Cost‐effectiveness analyses of natalizumab compared with other disease modifying therapies for people with highly active relapsing remitting multiple sclerosis. Pharmacoeconomics 2008; 26:616–627

3 Karnon J, Holmes MW, Williams R, et al. A cost utility analysis of clopidogrel in patients with ST elevation acute coronary syndrome. Int J Cardiol 2008; 140:315–322

4 Kendrick T, Chatwin J, Downick C, et al. Randomised controlled trial to determine the clinical effectiveness and cost‐effectiveness of selective serotonin reuptake inhibitors plus supportive care for mild to moderate depression and somatic symptoms in primary care. Health Technol Ass 2009; 13:22

5 Latimer N, Lord J, Grant R, et al. Cost‐effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. BMJ 2009; 339:2538–42

6 Rogers G, Garside R, Mealing S, et al. Carmustine implants for the treatment of newly diagnosed high grade gliomas. Pharmacoeconomics 2008; 26:33–44